This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leone, F. Articles by Aglietta, M. Search for Related Content PubMed PubMed Citation Articles by Leone, F. Articles by Aglietta, M.

Somatic Mutations of Epidermal Growth Factor Receptor in Bile Duct and Gallbladder Carcinoma

Authors' Affiliations: Departments of ¹ Clinical Oncology, ² Surgical Oncology and ³ Unit of Pathology, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo, Turin, Italy

Requests for reprints: Francesco Leone, Department of Clinical Oncology, Institute for Cancer Research and Treatment, Str. Prov.le 142 Km 3.95, 10060 Candiolo, Turin, Italy. Phone: 39-011-993-3628; Fax: 39-011-993-3524; E-mail: francesco.leone{at}ircc.it.

Objective: Conventional therapies are still unsuccessful in patients with carcinoma arising from the biliary tract. Somatic mutations of the epidermal growth factor receptor (EGFR) gene and the activation of its downstream pathways predict the sensitivity to small-molecule inhibitors in non–small cell lung carcinoma. Therefore, we analyzed EGFR mutations and related pathways in gallbladder and bile duct carcinomas to consider the possible application of these alternative therapeutic strategies.

Experimental Design: Forty paraffin-embedded samples, including intrahepatic or extrahepatic cholangiocarcinoma and gallbladder carcinoma, were studied after tumor cell isolation by laser microdissection and sequencing of EGFR tyrosine kinase domain (exons 18-21). Activation of EGFR pathway was studied by evaluating phosphorylation of mitogen-activated protein kinase and Akt.

Results: None of the 40 specimens had mutations in exon 18; one had one missense point mutation in exon 19, two in exon 20, and three in exon 21. In addition, 36 of 40 specimens had the same silent mutation at codon 787 in exon 20, which was also found in peripheral blood cells from healthy donors. Tumor samples harboring EGFR mutation had phosphorylation of one or both downstream transducers analyzed.

Conclusions: This is the first evidence of somatic mutations of the EGFR gene in bile duct carcinoma. Our findings suggest that a subgroup of patients with cholangiocarcinoma or gallbladder carcinoma exhibits somatic mutations of EGFR in the tyrosine kinase domain that can elicit cell signals sustaining survival and proliferation. These tumors might be further evaluated for their susceptibility to small-molecule inhibitor treatment.

This article has been cited by other articles:

				K. Ikeda, H. Nomori, T. Mori, J. Sasaki, and T. Kobayashi Novel Germline Mutation: EGFR V843I in Patient With Multiple Lung Adenocarcinomas and Family Members With Lung Cancer Ann. Thorac. Surg., April 1, 2008; 85(4): 1430 - 1432. [Abstract] [Full Text] [PDF]

				A. F. Hezel and A. X. Zhu Systemic Therapy for Biliary Tract Cancers Oncologist, April 1, 2008; 13(4): 415 - 423. [Abstract] [Full Text] [PDF]

				F. Leone, Y. Pignochino, G. Cavalloni, and M. Aglietta Targeting of Epidermal Growth Factor Receptor in Patients Affected by Biliary Tract Carcinoma J. Clin. Oncol., March 20, 2007; 25(9): 1145 - 1145. [Full Text] [PDF]

				P. A. Philip, M. R. Mahoney, C. Allmer, J. Thomas, H. C. Pitot, G. Kim, R. C. Donehower, T. Fitch, J. Picus, and C. Erlichman In Reply J. Clin. Oncol., March 20, 2007; 25(9): 1145 - 1146. [Full Text] [PDF]